Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating restated by Jefferies Group LLC in a research note issued to investors on Friday. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.39 EPS, FY2018 earnings at $2.79 EPS, FY2019 earnings at $3.21 EPS, FY2020 earnings at $3.63 EPS and FY2021 earnings at $4.00 EPS.
A number of other brokerages have also weighed in on ZTS. Morgan Stanley increased their target price on Zoetis from $61.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. BMO Capital Markets raised their price objective on Zoetis from $65.00 to $70.00 and gave the stock a “market perform” rating in a research note on Friday, November 3rd. BidaskClub upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Tuesday, November 7th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research note on Tuesday, October 24th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a research note on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $67.06.
Zoetis (ZTS) opened at $69.13 on Friday. The firm has a market capitalization of $33,769.08, a P/E ratio of 31.79, a PEG ratio of 2.03 and a beta of 1.02. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. Zoetis has a 52 week low of $48.24 and a 52 week high of $70.48.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.52 earnings per share. research analysts expect that Zoetis will post 2.36 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Jefferies Group LLC Reiterates “Buy” Rating for Zoetis Inc. (ZTS)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/jefferies-group-llc-reiterates-buy-rating-for-zoetis-inc-zts.html.
Institutional investors and hedge funds have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. increased its stake in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the last quarter. Harfst & Associates Inc. increased its stake in shares of Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares during the last quarter. Almanack Investment Partners LLC. bought a new position in shares of Zoetis in the 2nd quarter valued at $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the last quarter. Finally, Peddock Capital Advisors LLC acquired a new stake in shares of Zoetis during the 2nd quarter valued at $140,000. Institutional investors own 92.90% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.